Cargando…

Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions

BACKGROUND: Evidence supporting treatment intensification in rheumatoid arthritis (RA) is limited and controversial. We explored outcomes of infliximab dose increases and accounted for pre-existing trough levels in patients with active RA. METHODS: This study was a retrospective study of 42 RA patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Plasencia, Chamaida, Jurado, Teresa, Villalba, Alejandro, Peitedado, Diana, Casla, Maria Teresa López, Nuño, Laura, Bonilla, María Gema, Martínez-Feito, Ana, Martín-Mola, Emilio, Pascual-Salcedo, Dora, Balsa, Alejandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597116/ https://www.ncbi.nlm.nih.gov/pubmed/26501060 http://dx.doi.org/10.3389/fmed.2015.00071

Ejemplares similares

Predictive Value of Serum Infliximab Levels at Induction Phase in Rheumatoid Arthritis Patients
por: Jurado, Teresa, et al.
Publicado: (2017)

The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients
por: Plasencia, Chamaida, et al.
Publicado: (2013)

Methotrexate Reduces the Probability of Discontinuation of TNF Inhibitors in Seropositive Patients With Rheumatoid Arthritis. A Real-World Data Analysis
por: Hernández-Breijo, Borja, et al.
Publicado: (2021)

Constitutively altered frequencies of circulating follicullar helper T cell counterparts and their subsets in rheumatoid arthritis
por: Arroyo-Villa, Irene, et al.
Publicado: (2014)

Low Serum BAFF Concentration Is Associated with Response to TNF Inhibitors in Seropositive Patients with Rheumatoid Arthritis
por: Hernández-Breijo, Borja, et al.
Publicado: (2022)

Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis
por: Rodríguez-Martín, Eulalia, et al.
Publicado: (2020)

Risk Factors for Developing Rheumatoid Arthritis in Patients With Undifferentiated Arthritis and Inflammatory Arthralgia
por: Novella-Navarro, Marta, et al.
Publicado: (2021)

BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors
por: Hernández-Breijo, Borja, et al.
Publicado: (2021)

Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis
por: Hernández-Breijo, Borja, et al.
Publicado: (2021)

Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar
por: Martínez-Feito, Ana, et al.
Publicado: (2020)

Comparison of long-term efficacy between biological agents following tumor necrosis factor inhibitor failure in patients with rheumatoid arthritis: a prospective cohort study
por: Bogas, Patricia, et al.
Publicado: (2021)

Comment on: Telemedicine in the management of rheumatoid arthritis: maintaining disease control with less health-care utilization
por: Benavent, Diego, et al.
Publicado: (2021)

Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis
por: Hernández-Breijo, Borja, et al.
Publicado: (2019)

Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b/tsDMARD treatment
por: Novella -Navarro, Marta, et al.
Publicado: (2023)

Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis
por: Novella-Navarro, Marta, et al.
Publicado: (2020)

Coping with rheumatic stressors (CORS) questionnaire: Spanish translation and cross-cultural adaptation
por: Benavent, Diego, et al.
Publicado: (2023)

Predictive model to identify multiple failure to biological therapy in patients with rheumatoid arthritis
por: Novella-Navarro, Marta, et al.
Publicado: (2022)

Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients
por: Regueiro, Cristina, et al.
Publicado: (2017)

Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factor
por: Balsa, Alejandro, et al.
Publicado: (2010)

Improved RA classification among early arthritis patients with the concordant presence of three RA autoantibodies: analysis in two early arthritis clinics
por: Regueiro, Cristina, et al.
Publicado: (2019)

Frequency of Th17 CD4+ T Cells in Early Rheumatoid Arthritis: A Marker of Anti-CCP Seropositivity
por: Arroyo-Villa, Irene, et al.
Publicado: (2012)

Immune response after SARS-CoV-2 vaccination in patients with inflammatory immune-mediated diseases receiving immunosuppressive treatment
por: Plasencia-Rodríguez, Chamaida, et al.
Publicado: (2023)

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
por: van der Maas, Aatke, et al.
Publicado: (2012)

Crosstalk between synovial fibroblasts and T lymphocytes in rheumatoid arthritis: effect of methotrexate
por: Miranda, E, et al.
Publicado: (2003)

Achievement rate and predictive factors of the recommended therapeutical target in patients with axial spondyloarthritis who remain on biological therapy: a prospective cohort study in Spain
por: Benavent, Diego, et al.
Publicado: (2022)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Improved classification of rheumatoid arthritis with a score including anti-acetylated ornithine antibodies
por: Rodriguez-Martínez, Lorena, et al.
Publicado: (2020)

Increased frequency of circulating CD19+CD24(hi)CD38(hi) B cells with regulatory capacity in patients with Ankylosing spondylitis (AS) naïve for biological agents
por: Bautista-Caro, María-Belén, et al.
Publicado: (2017)

Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review
por: Navarro-Compán, Victoria, et al.
Publicado: (2017)

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab
por: Sorrentino, Dario, et al.
Publicado: (2015)

Decreased Frequencies of Circulating Follicular Helper T Cell Counterparts and Plasmablasts in Ankylosing Spondylitis Patients Naïve for TNF Blockers
por: Bautista-Caro, María-Belén, et al.
Publicado: (2014)

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy
por: Huang, Vivian W., et al.
Publicado: (2015)

Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study
por: Takeuchi, Tsutomu, et al.
Publicado: (2009)

Treatment of acute severe ulcerative colitis using accelerated infliximab regimen based on infliximab trough level: A case report
por: Garate, Ana Lorena Sousa de Vasconcelos, et al.
Publicado: (2021)

Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy
por: Cao, Wan-Ting, et al.
Publicado: (2022)

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
por: Choi, So Yoon, et al.
Publicado: (2023)

Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
por: Theodoraki, Eirini, et al.
Publicado: (2021)

Infliximab Trough Levels and Quality of Life in Patients with Inflammatory Bowel Disease in Maintenance Therapy
por: Parra, Rogério S., et al.
Publicado: (2018)

Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment
por: Rolandsdotter, Helena, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_00mep0f9dj5e625u5m2ltte6mm